Fulgent Genetics (FLGT) Payables (2015 - 2026)

Fulgent Genetics (FLGT) has 12 years of Payables data on file, last reported at $21.6 million in Q1 2026.

• Quarterly Payables rose 15.46% year-over-year to $21.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $21.6 million (up 15.46% YoY) and the FY2025 annual result came in at $19.1 million, up 1.89% from the prior year.
• Payables climbed to $21.6 million in Q1 2026 per FLGT's latest filing, from $19.1 million in the prior quarter.
• The five-year high for Payables was $42.9 million in Q2 2022, with the low at $16.5 million in Q4 2023.
• Average Payables over 5 years is $22.7 million, with a median of $20.0 million recorded in 2024.
• Year-over-year, Payables surged 191.0% in 2022 and plunged 42.42% in 2023.
• Fulgent Genetics' Payables stood at $28.7 million in 2022, then sank by 42.42% to $16.5 million in 2023, then rose by 13.5% to $18.8 million in 2024, then climbed by 1.89% to $19.1 million in 2025, then advanced by 12.95% to $21.6 million in 2026.
• Business Quant data shows FLGT's Payables at $21.6 million in Q1 2026, $19.1 million in Q4 2025, and $18.6 million in Q3 2025.